Stockscreener 앱 받기
40.07
2.74%
1.07
시간 외 거래:
40.07
전일 마감가:
$39.00
열려 있는:
$38.91
하루 거래량:
407.55K
Relative Volume:
1.05
시가총액:
$1.17B
수익:
$219.79M
순이익/손실:
$-57.47M
주가수익비율:
-18.64
EPS:
-2.15
순현금흐름:
$-19.25M
1주 성능:
+1.93%
1개월 성능:
+3.70%
6개월 성능:
+97.39%
1년 성능:
+36.48%
1일 변동 폭
$37.29
$40.27
1주일 범위
$37.29
$40.27
52주 변동 폭
$14.59
$42.17
Castle Biosciences Inc Stock (CSTL) Company Profile
명칭
Castle Biosciences Inc
전화
866-788-9007
주소
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
CSTL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
40.07 | 1.14B | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
620.72 | 229.63B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
236.59 | 166.25B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
706.83 | 54.48B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
147.60 | 40.52B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
240.53 | 39.95B | 15.90B | 1.28B | 2.21B | 7.2842 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-04-30 | 개시 | Lake Street | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | 재확인 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | BTIG Research | Buy |
| 2019-08-19 | 개시 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | Robert W. Baird | Outperform |
| 2019-08-19 | 개시 | SVB Leerink | Outperform |
모두보기
Castle Biosciences Inc 주식(CSTL)의 최신 뉴스
What drives Castle Biosciences Inc stock priceWeekly Market Snapshot & Affordable Trading Plans - earlytimes.in
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 830 Shares - MarketBeat
Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus - Yahoo Finance
Is Castle Biosciences Inc. stock vulnerable to regulatory risksHealthcare Stock Analysis & Free Professional Investment Consultations - bollywoodhelpline.com
Breakouts Watch: Why Castle Biosciences Inc. stock is considered a top pick2025 Sector Review & Real-Time Volume Triggers - moha.gov.vn
What makes Castle Biosciences (CSTL) a good fit for 'trend investing' - MSN
What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing' - sharewise.com
Is Castle Biosciences (NASDAQ:CSTL) Using Too Much Debt? - 富途牛牛
Castle Biosciences stock hits 52-week high at 40.66 USD - Investing.com
Castle Biosciences (NASDAQ:CSTL) Hits New 12-Month High After Analyst Upgrade - MarketBeat
Castle Biosciences stock hits 52-week high at 40.66 USD By Investing.com - Investing.com Nigeria
Castle Biosciences (CSTL) Receives Analyst Rating Update with Ra - GuruFocus
Castle Biosciences (NASDAQ:CSTL) Given New $50.00 Price Target at Canaccord Genuity Group - MarketBeat
Is Castle Biosciences Inc. stock a top momentum playWeekly Investment Recap & Safe Swing Trade Setup Alerts - Улправда
Why Castle Biosciences Inc. stock is favored by top institutionsJuly 2025 Chart Watch & Smart Investment Allocation Tips - Улправда
Is Castle Biosciences Inc. stock positioned for digital transformationJuly 2025 Analyst Calls & Risk Controlled Swing Alerts - Улправда
Castle Biosciences (NASDAQ:CSTL) Insider Sells $20,380.36 in Stock - MarketBeat
Castle Biosciences (NASDAQ:CSTL) COO Kristen Oelschlager Sells 14,888 Shares - MarketBeat
Why retail investors favor Castle Biosciences Inc. stockPortfolio Value Summary & Fast Momentum Entry Tips - Улправда
Can Castle Biosciences Inc. stock continue upward trend2025 Biggest Moves & Advanced Swing Trade Entry Alerts - DonanımHaber
Castle Biosciences (CSTL) Awards Restricted Stock Units to New E - GuruFocus
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Castle Biosciences reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule - TradingView — Track All Markets
Can Castle Biosciences Inc. stock maintain operating marginsTrade Entry Report & Fast Exit and Entry Trade Guides - Улправда
Is Castle Biosciences Inc. stock a buy before product launchesMarket Trend Review & Real-Time Volume Analysis - Улправда
Is Castle Biosciences Inc. stock trading at a premium valuationJuly 2025 Price Swings & Long-Term Safe Return Strategies - Улправда
Squarepoint Ops LLC Buys 28,359 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat
COO Oelschlager Files To Sell 14,888 Of Castle Biosciences Inc [CSTL] - TradingView — Track All Markets
Castle Biosciences (CSTL) CEO reports stock sales under 10b5-1 plan - Stock Titan
Castle Biosciences’ melanoma test outperforms NGS in eye cancer study By Investing.com - Investing.com Nigeria
Castle Biosciences (CSTL) Reveals Enhanced Predictive Method for Uveal Melanoma Outcomes - GuruFocus
Castle Biosciences’ melanoma test outperforms NGS in eye cancer study - Investing.com
Castle Biosciences Announces Key Study Findings on Uveal Melanoma Risk Stratification Using DecisionDx-UM and PRAME Combination - Quiver Quantitative
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma - GlobeNewswire
CFO Stokes Sells 4,496 ($168.4K) Of Castle Biosciences Inc [CSTL] - TradingView — Track All Markets
Castle Biosciences (CSTL) CCO reports sale of 13,200 shares - Stock Titan
Castle Biosciences (CSTL): Valuation Check After Expert Panel Endorses DecisionDx-Melanoma Test - Yahoo Finance
Castle Biosciences (NASDAQ:CSTL) Given New $50.00 Price Target at BTIG Research - MarketBeat
Castle Biosciences, Inc. $CSTL Shares Bought by Braidwell LP - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Castle Biosciences (CSTL) Highlights Breakthrough in Barrett's E - GuruFocus
Castle Biosciences Announces Publication of Study Confirming TissueCypher® Test's Efficacy in Risk Stratification for Barrett's Esophagus Patients - Quiver Quantitative
BTIG Maintains Castle Biosciences (CSTL) Buy Recommendation - Nasdaq
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer - GlobeNewswire
Castle Biosciences (NASDAQ: CSTL) CCO reports RSU settlements and share disposals - Stock Titan
Castle Biosciences Inc (CSTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.85%
자본화:
|
볼륨(24시간):